Prosecution Insights
Last updated: July 17, 2026
Application No. 17/790,951

METHODS FOR DIAGNOSING EXPOSURE TO COLORECTAL CANCER CARCINOGENS USING BIOLOGICAL SAMPLES

Non-Final OA §112
Filed
Oct 26, 2022
Priority
Jan 08, 2020 — RE 10-2020-0002492 +1 more
Examiner
BERKELEY, EMILY R
Art Unit
1796
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Goodbeing Center Co. Ltd.
OA Round
3 (Non-Final)
76%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 76% — above average
76%
Career Allowance Rate
314 granted / 413 resolved
+11.0% vs TC avg
Strong +28% interview lift
Without
With
+28.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 1m
Avg Prosecution
26 currently pending
Career history
437
Total Applications
across all art units

Statute-Specific Performance

§101
2.0%
-38.0% vs TC avg
§103
68.4%
+28.4% vs TC avg
§102
12.2%
-27.8% vs TC avg
§112
12.7%
-27.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 413 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . An amendment and RCE filed 5/22/2026 are acknowledged. Claims 1, 2, 4, 5, and 9 are pending. Claims 3 and 6-8 are cancelled. Claim 9 is new. Claims 1, 2, 4, 5, and 9 are considered on the merits below. Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 5/22/2026 has been entered. Response to Amendment Applicant's amendments, filed 5/22/2026, with respect to the objection to the drawings and 101 rejection, have been fully satisfied and withdrawn. In response to the applicant's amendments, the grounds of rejection for claims 1, 2, 4, 5, and 9 are new compared to the previous action. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1, 2, 4, 5, and 9 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. Regarding claim 1, the limitation “simultaneously quantifying” is new matter. Looking to the instant specification and drawings, there is evidence that both PhIP and MeIQx are quantified, but nothing to indicate “simultaneously”. Thus the amendment fails to comply with the written description requirement. Dependent claims follow the same reasoning. Response to Arguments Applicant’s arguments with respect to claims 1, 2, 4, 5, and 9 have been considered but are moot because the arguments do not apply to the current rejection. Regarding the 101 rejection, the amendment to the claims to include specific parameters of hydrolyzing the biological sample, as well as requiring an LC/MS/MS for quantification, are sufficient to overcome the rejection as it now requires the quantification to be more than an mental step. Regarding the 102 rejection, the amendments to the claims to include “simultaneously quantifying” are sufficient to overcome the prior art rejections. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to EMILY R BERKELEY whose telephone number is (571)272-9831. The examiner can normally be reached M-Th 9-6. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Lyle Alexander can be reached at (571) 272-1254. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /LYLE ALEXANDER/Supervisory Patent Examiner, Art Unit 1797 /EMILY R. BERKELEY/ Examiner Art Unit 1796
Read full office action

Prosecution Timeline

Oct 26, 2022
Application Filed
Aug 27, 2025
Non-Final Rejection mailed — §112
Nov 18, 2025
Response Filed
Feb 25, 2026
Final Rejection mailed — §112
May 22, 2026
Request for Continued Examination
May 22, 2026
Response after Non-Final Action
Jul 09, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12673324
SURFACTANT ADDITIVES FOR DIGITAL MICROFLUIDIC DEVICES FOR HIGH PROTEIN CONTENT DROPLETS TRANSPORT
4y 3m to grant Granted Jul 07, 2026
Patent 12674801
BIOCHIP AND DETECTION METHOD
4y 2m to grant Granted Jul 07, 2026
Patent 12663426
METHOD AND COMPOSITION FOR MEASUREMENT OF NITRIC OXIDE
4y 0m to grant Granted Jun 23, 2026
Patent 12636651
CONTAINER FOR SELECTIVE TRANSFER OF SAMPLES OF BIOLOGICAL MATERIAL
4y 2m to grant Granted May 26, 2026
Patent 12638394
SKIN SENSITIZATION MEASURING REAGENT, METHOD FOR MEASURING SKIN SENSITIZATION, AND COMPOUND
4y 2m to grant Granted May 26, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
76%
Grant Probability
99%
With Interview (+28.0%)
3y 1m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 413 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month